Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Organicell Regenerative Medicine, Inc. | organicell_ex32-2.htm |
| EX-31.2 - EXHIBIT 31.2 - Organicell Regenerative Medicine, Inc. | organicell_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Organicell Regenerative Medicine, Inc. | organicell_ex31-1.htm |
| 10-Q - 10-Q - Organicell Regenerative Medicine, Inc. | organicell_10q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Organicell Regenerative Medicine, Inc. on Form 10-Q for the quarter ended July 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Albert Mitrani, Chief Executive Officer and President of Organicell Regenerative Medicine, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Biotech Products Services and Research, Inc. |
| Date: September 14, 2021 | /s/ ALBERT MITRANI |
| Albert Mitrani | |
| Chief Executive Officer | |
| (Principal Executive Officer) |